Protease profiling of liver fibrosis reveals the adam metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of TGF-β

Archive ouverte

Bourd-Boittin, Katia | Bonnier, Dominique | Leyme, Anthony | Mari, Bernard | Tuffery, Pierre | Samson, Michel | Ezan, Frédéric | Baffet, Georges | Theret, Nathalie

Edité par CCSD ; Wiley-Blackwell -

International audience. During chronic liver disease, tissue remodeling leads to dramatic changes and accumulation of matrix components. Matrix metalloproteases and their inhibitors have been involved in the regulation of matrix degradation. However, the role of other proteases remains incompletely defined. We undertook a gene expression screen of human liver fibrosis samples using a dedicated gene array selected for relevance to protease activities, identifying the ADAMTS1 (ADAM metallopeptidase with thrombospondin type 1 motif, 1) gene as an important node of the protease network. Upregulation of ADAMTS1 in fibrosis was found to be associated with hepatic stellate cell (HSC) activation. ADAMTS1 is synthesized as 110-kDa latent forms and processed by HSCs to accumulate as 87-kDa mature forms in fibrotic tissues. Structural evidence suggested that the thrombospondin motif-containing domain from ADAMTS1 may be involved in interactions with, and activation of, the major fibrogenic cytokine, TGF-β. Indeed, we observed direct interactions between ADAMTS1 and latency-associated peptide-TGF-β (LAP-TGF-β). ADAMTS1 induces TGF-β activation through the interaction of the ADAMTS1 KTFR peptide with the LAP-TGF-β LKSL peptide. Down-regulation of ADAMTS1 in HSCs decreases the release of TGF-β competent for transcriptional activation and KTFR competitor peptides directed against ADAMTS1 block HSC-mediated release of active TGF-β. Using a mouse liver fibrosis model, we show that CCl(4) treatment induces ADAMTS1 expression in parallel to that of type I collagen. Importantly, concurrent injection of the KTFR peptide prevents liver damage. CONCLUSION: Our results indicate that up-regulation of ADAMTS1 in HSCs constitutes a new mechanism for control of TGF-β activation in chronic liver disease. (HEPATOLOGY 2011.).

Consulter en ligne

Suggestions

Du même auteur

ADAM10, ADAM17 and MMP2 activities in hepatic stellate Cells are involved in CX3CL1 processing and contribute to chronic liver injury

Archive ouverte | Bourd-Boittin, Katia | CCSD

ILK, a new partner for ADAM12 in cell adhesion and survival

Archive ouverte | Leyme, Anthony | CCSD

National audience

Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell adhesion and survival.. Identification of ILK as a new partner of the ADAM12 disintegrin and metalloprotease in cell adhesion and survival.: ADAM12-ILK interaction

Archive ouverte | Leyme, Anthony | CCSD

International audience. Based on its shedding and binding activities, the disintegrin and metalloprotease 12 (ADAM12) has been implicated in cell signaling. Here we investigate the intracellular protein interaction ...

Chargement des enrichissements...